A gene normally involved in the regulation of embryonic development can trigger the transition of cells into more mobile types that can spread without regard for the normal biological controls that restrict metastasis, the new study shows. …
Chronic pancreatitis (CP) is an inflammatory disease that over time leads to loss of function of the pancreas and manifests with intractable pain, malabsorption and diabetes. While medical management and pain control are the initial approaches to CP, some patients need to undergo more invasive procedures to relieve ductal pressure in the pancreas. If those measures fail, surgical options can include total removal of the pancreas (total pancreatectomy, TP) or the Whipple procedure to remove part of the pancreas. Total pancreas removal produces diabetes because insulin-secreting cells are removed…
And once the sleep was lost, there was no getting its positive effect back by allowing extra rest later. In “Recovery Sleep Does Not Mitigate the Effects of Prior Sleep Loss on Paclitaxel-Induced Mechanical Hypersensitivity in Sprague-Dawley Rats,” a preclinical study published in Biological Research for Nursing, restricted sleep among rats led to worse reactions to PAC, associated with painful, debilitating peripheral neuropathy of the hands and feet that may persist long after therapy is completed. According to the study, “How poor sleep sets the stage for adverse outcomes among people diagnosed with cancer is not entirely understood…
An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in PFS for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment, letrozole, and palbociclib compared to letrozole alone. “We’re essentially putting the brakes on cell proliferation and causing these tumor cells to stop growing,” said Dr. …
They found that patients were rarely involved in the decision to be referred for investigation and that reasons for referral tended to be couched in non-specific terms rather than ‘cancer investigation’, even when the patient was on a cancer-specific pathway. The National Institute for Health and Care Excellence (NICE) referral guidelines emphasise that the patient should be involved in the decision-making process and be informed of the reasons for referral…
The benign hyperplastic polyp appears very pale and bland on imaging. Their 522-patient study, published in the December issue of Gastrointestinal Endoscopy, found that physicians correctly evaluated whether a polyp was precancerous or benign using high-definition optical lenses during a colonoscopy…
The new technique cuts out a cellular middleman. Study senior author Xiaowei “George” Xu, MD, PhD, an associate professor of Pathology and Laboratory Medicine, explains, “Through direct reprogramming, we do not have to go through the pluripotent stem cell stage, but directly convert fibroblasts to melanocytes. …
An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in PFS for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment, letrozole, and palbociclib compared to letrozole alone. …
A better, cheaper, and safer way to look for the telltale signs of breast cancer may be with microwaves, said Neil Epstein, a NSERC CREATE I3T postdoctoral fellow at the University of Calgary in Canada. Epstein and his colleagues–engineering professor Paul Meaney of Dartmouth College’s Thayer School of Engineering and Keith Paulsen, director of the Dartmouth Advanced Imaging Center and the Robert A. …
“We found that adding either carboplatin or bevacizumab to standard preoperative chemotherapy increased pathologic complete response rates for women with basal-like cancers — that is, it increased the proportion of women who had no residual cancer detected at surgery. At the same time, we found that while carboplatin had a similar effect in the smaller group of triple-negative patients with nonbasal-like cancers, adding bevacizumab actually decreased response rates for women with nonbasal-like cancers,” says William M. Sikov, MD, associate chief of clinical research with the Program in Women’s Oncology at Women & Infants and associate professor of medicine at The Warren Alpert Medical School of Brown University…